Substance and non substance related addiction disorders : diagnosis and treatment / edited by, Subhash C. Bhatia ; co-editors, Frederick Petty & Teri Gabel.

Format:

Book

Author/Creator:

Bhatia, Subhash C, Author.

Contributor:

Bhatia, Subhash C., editor.

Petty, Frederick, editor.

Gabel, Teri, editor.

Language:

English

Subjects (All):

Neurobiology--Congresses.

Neurobiology.

Physical Description:

1 online resource (274 pages) : illustrations

Edition:

1st ed.

Place of Publication:

Sharjah, United Arab Emirates : Bentham Science Publishers, 2017.

Summary:

Substance and Non substance Related Addiction Disorders: Diagnosis and Treatment is an accessible handbook about the two main types of addiction disorders. It is divided into three sections which cover 1) the scientific underpinnings of addiction disorders (neurobiology addiction neural reward pathways genetic and psychosocial basis of addiction screening and treatment) 2) information about substances commonly used by addicts (pharmacology diagnostics and treatment considerations) and 3) current understandings of the diagnosis and treatment of behavioral problems (such as gambling) respectively. Key features: -covers both substance abuse and behavioral problems -uses a reader friendly format with a patient education handout style -includes key learning points listed in each chapter -includes clinical vignettes which outline brief history evaluation diagnostic considerations with successful pharmacological psychological and social interventions -includes references in each chapter The handbook meets the information needs of medical students and professionals (family physicians nurses addiction therapists psychiatry residents and other health care professionals) interested in the primary care of patients afflicted with addiction disorders.

Contents:

Intro

CONTENTS

FOREWORD

PREFACE

List of Contributors

Section I: General Topics

Neurobiology and Psycho-Social Basis for Addiction and Related Disorders

KEY LEARNING POINTS

NEUROBIOLOGY OF ADDICTION AND REWARD PATHWAYS

PSYCHOSOCIAL FACTORS

ADVERSE CHILDHOOD EXPERIENCES (ACE)

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

REFERENCES

Urine Drug Screening (UDS) in the Management of Substance Use Disorders

CLINICAL VIGNETTE

DIAGNOSTIC CONSIDERATION

REASONS FOR OBTAINING AN UDS

URINE DRUG SCREENS

Types of Urine Drug Tests

Urine Drug Test as a Follow-up Tool

Urine Sample Collection

Chain of Custody

Medication Interfering with UDS

SPECIAL CONSIDERATIONS

Opiate/Opioid Metabolism

Benzodiazepines

Untested Substances

Altered Pharmacokinetic and Pharmacodynamic Parameters

SUMMARY

PATIENT INFORMATION SHEET - URINE DRUG SCREENS

Genetics of Addiction

GENETICS OF ADDICTION

PATIENT EDUCATION SHEET

Dual Diagnosis

BACKGROUND

DIAGNOSTIC CONSIDERATIONS

TREATMENT CONSIDERATIONS

TREATMENT OUTCOMES

DUAL DIAGNOSIS - PATIENT INFORMATION SHEET

Pharmacologic Treatment for Psychiatric Disorders Associated with Substance Use Disorders: An Overview

INTRODUCTION

Benzodiazepines (Table 1)

Antidepressants

Serotonin Syndrome

Syndrome Presentation

Treatment

SSRI Withdrawal Phenomenon

Atypical/Typical Antipsychotics

Dosing

Monitoring

Additional Monitoring Recommended

Other Side Effects

Extrapyramidal Side Effects (EPSE).

Treatment of Early - EPSE

Dystonias and Pseudoparkinsonism

Akathisia

Treatment of Tardive Dyskinesia

Neuroleptic Malignancy Syndrome (NMS)

Mood Stabilizers

Anticonvulsants

Management of Insomnia

PATIENT INFORMATION - MEDICATIONS FOR SUBSTANCE USE DISORDERS

Motivational Interviewing

PROCESS

MOTIVATION ENHANCEMENT

THE STAGES OF CHANGE

MOTIVATIONAL INTERVIEW-PATIENT EDUCATION SHEET

Section II: Substance-Related Addiction Disorders (Alphabetical)

Alcohol Use Disorders

KEY POINTS

Epidemiology

Etiology

Diagnosis

Non-Pharmacologic Interventions

Pathophysiology of Alcohol Use Disorders (AUD)

PHARMACOTHERAPY FOR ALCOHOL USE DISORDERS (AUD)

Management of Outpatient Alcohol Withdrawal

FDA Approved Medications for Alcohol Use Disorder [26]

Disulfiram (Antabuse®) [19, 21, 27]

Naltrexone (Revia® (PO), Vivitrol® (IM))

Acamprosate (Campral®) [21, 28, 30]

Combination Therapy

Non-FDA Approved Pharmacotherapies for AD

CLINICAL VIGNETTE RESOLUTION

PROVIDER RESOURCES

ALCOHOL USE DISORDERS: PATIENT EDUCATION SHEET

PATIENT RESOURCES

Anabolic-Androgenic Steroids (AAS) Related Disorders

EPIDEMIOLOGY

DIAGNOSIS, AND CLINICAL PRESENTATION

PHYSIOLOGY AND PHARMACOLOGY

BIO-PSYCHO-SOCIAL TREATMENT

Pharmacological Treatment of Anabolic Steroids Disorders

Psycho-Social Interventions

ANABOLIC ANDROGENIC STEROIDS - PATIENT INFORMATION SHEET

RESOURCES

REFERENCES.

Caffeine Related Use Disorder

DISCUSSION OF THE VIGNETTE

Recognition

CLINICAL PSYCHOPHARMACOLOGY

MEDICAL EFFECTS OF CAFFEINE

CONCLUSION

PATIENT INFORMATION - EDUCATION SHEET

Cannabis and Cannabinoid Use Disorders

MEDICAL EFFECTS WITH CANNABIS

PHARMACOLOGICAL INTERVENTIONS

PSYCHOLOGICAL INTERVENTIONS

SOCIAL INTERVENTIONS

CANNABIS-RELATED DISORDERS- PATIENT EDUCATION SHEET

Ecstasy Substance Use Disorder

NEUROPSYCHOPHARMACOLOGY

MDMA INTOXICATION

Psychological Effects

Physical Effects

TREATMENT

Pharmacotherapy

Psychosocial Interventions

MDMA - PATIENT EDUCATION SHEET

Hallucinogen-LSD Use Disorder

DISCUSSION OF CASE VIGNETTE

NEUROBIOLOGY OF LSD USE DISORDER

LSD INTOXICATION SYNDROME

TREATMENT OF LSD USE AND LSD-INDUCED DISORDERS

LSD - PATIENT EDUCATION SHEET

Inhalant Use Disorders

CLINICAL PSYCHOPHARMACOLOGY.

MEDICAL AND PSYCHIATRIC CONSEQUENCES OF INHALANT USE DISORDERS

INHALANT USE DISORDER- PATIENT EDUCATION SHEET

Opioid Use and Addictive Disorder

Co-occurring Psychiatric and other Substance Use Disorder(s)

Co-occurring Medical Disorders

DIAGNOSIS AND CLINICAL PRESENTATION [7]

Opioid Related Disorders

NEUROBIOLOGY OF OPIOID USE DISORDERS

PHARMACOLOGICAL TREATMENT OF OPIOID USE DISORDERS

Management of Acute Intoxication

FDA Approved Agents for Detoxification and Maintenance Treatment

Methadone (Dolophine®, Methadose®)

Buprenorphine (Subutex®) and Buprenorphine and Naloxone (Suboxone®)

Naltrexone

MANAGING DETOXIFICATION

MAINTENANCE TREATMENT

Monitoring the Patient on Methadone and Buprenorphine [42]

Clinical Vignette Resolution

OPIOID USE DISORDER- PATIENT INFORMATION SHEET

Phencyclidine (PCP) Use Disorder

DISCUSSION OF VIGNETTE

PCP INTOXICATION

TREATMENT OF PCP USE AND PCP INDUCED DISORDERS

PCP - PATIENT EDUCATION SHEET

Sedative, Hypnotic or Anxiolytic-Related Disorders

Diagnostic Considerations

Management Considerations

SEDATIVE, HYPNOTIC OR ANXIOLYTIC-RELATED DISORDERS IN DSM-5

PHARMACOLOGICAL DEPENDENCE VS. ADDICTION.

FACTORS THAT MAY CONTRIBUTE TO SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE DISORDER

Patient Related Factors

Drug Pharmacokinetic or Pharmacodynamics Related Factors

Drug Availability Related Factor

Sedative, Hypnotic or Anxiolytic Use Disorders: Risk Reduction

Managing Withdrawal

PROMOTING RECOVERY

Pharmacological Interventions

Psychological Interventions

Social Interventions

BENZODIAZEPINES - PATIENT EDUCATION HANDOUT

Stimulant Use and Addictive Disorder: Amphetamine, Cocaine and Other Stimulants

Cocaine and Stimulant Related Disorders

MEDICAL ISSUES WITH COCAINE AND STIMULANTS

Detoxification Pharmacotherapy

Relapse Prevention Pharmacotherapy

STIMULANT RELATED DISORDERS - PATIENT EDUCATION SHEET

Tobacco Use Disorders

RECOGNITION

DIAGNOSTIC ELEMENTS PRESENTED

PHARMACOLOGICAL TREATMENT

Nicotine Replacement Therapy

Bupropion (Zyban, Wellbutrin)

Varenicline (Chantix)

Other Agents

Bio-psycho-social Treatment

Psychosocial Aspects of Nicotine Cessation

Support Groups

Self Help Groups

Telephone Quitlines

Treatment Outcome as it Relates to the Vignette

TOBACCO USE DISORDER: PATIENT EDUCATION SHEET

Section III : Non Substance-Related Addiction Disorders

Non-Substance-Related Addictive Disorders

CLINICAL VIGNETTE.

Discussion of Vignette.

Notes:

Includes bibliographical references and index.

Description based on online resource; title from PDF title page (ebrary, viewed March 20, 2017).

ISBN:

9781681083438

1681083434